Amit Meller, an associate professor of biomedical engineering and physics at BU, is a founder of NobleGen Biosciences, a new startup that aims to commercialize nanopore sequencing technology he developed (see article, this issue). His co-founders are Ory Zik, a serial entrepreneur, and Zeev Pearl, an intellectual property lawyer.
Frank Feist is the founding CEO of NobleGen. Most recently, he headed the commercial team of Advalytix, which was acquired by Olympus in 2005 and became part of Beckman Coulter Genomics last year. He holds an MBA from the MIT Sloan School of Management and an MS in electrical and computer engineering from the University of Massachusetts, Amherst.
Phil Buzby recently joined NobleGen as vice president of biochemistry. Until 2008, he was a senior director of intellectual property at Helicos BioSciences, and before that, a senior director of nucleic acid chemistry at Helicos. He holds a PhD in biochemistry from Washington Sate University and a BS in biochemistry and biology from Iowa State University.